271 related articles for article (PubMed ID: 25098682)
1. Update on systemic therapy of advanced non-small-cell lung cancer.
Cufer T; Knez L
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1189-203. PubMed ID: 25098682
[TBL] [Abstract][Full Text] [Related]
2. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
4. Directed therapies in lung cancer: new hope?
Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
Minguet J; Smith KH; Bramlage P
Int J Cancer; 2016 Jun; 138(11):2549-61. PubMed ID: 26537995
[TBL] [Abstract][Full Text] [Related]
6. ALK inhibitors and advanced non-small cell lung cancer (review).
Rossi A; Maione P; Sacco PC; Sgambato A; Casaluce F; Ferrara ML; Palazzolo G; Ciardiello F; Gridelli C
Int J Oncol; 2014 Aug; 45(2):499-508. PubMed ID: 24889366
[TBL] [Abstract][Full Text] [Related]
7. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
9. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
10. Personalized medicine for non-small-cell lung cancer.
Mok TS; Zhou Q; Leung L; Loong HH
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
[TBL] [Abstract][Full Text] [Related]
11. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
Soria JC; Mok TS; Cappuzzo F; Jänne PA
Cancer Treat Rev; 2012 Aug; 38(5):416-30. PubMed ID: 22119437
[TBL] [Abstract][Full Text] [Related]
12. Oncogene addicted non-small-cell lung cancer: current standard and hot topics.
Vecchiarelli S; Bennati C
Future Oncol; 2018 Jun; 14(13s):3-17. PubMed ID: 29989448
[TBL] [Abstract][Full Text] [Related]
13. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Sequist LV; Bell DW; Lynch TJ; Haber DA
J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
[TBL] [Abstract][Full Text] [Related]
14. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli C
Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
[No Abstract] [Full Text] [Related]
15. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
Cottini F; Lautenschlaeger T
Cancer J; 2013; 19(3):263-71. PubMed ID: 23708073
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy in lung cancer: survival, quality of life improved for some patients.
Printz C
Cancer; 2014 Sep; 120(17):2625-6. PubMed ID: 25142921
[No Abstract] [Full Text] [Related]
17. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Arbour KC; Riely GJ
JAMA; 2019 Aug; 322(8):764-774. PubMed ID: 31454018
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.
Cadranel J; Ruppert AM; Beau-Faller M; Wislez M
Crit Rev Oncol Hematol; 2013 Dec; 88(3):477-93. PubMed ID: 23911281
[TBL] [Abstract][Full Text] [Related]
20. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
Wijesinghe P; Bollig-Fischer A
Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
